Jin Biotech is a developer of animal pharmaceuticals and functional additives. When added to animal feed, it performs various functions such as antibacterial and antibiotic effects, immune enhancement, and reduction of contamination and odors through the decomposition of pollutants. The animal pharmaceutical and functional additive industry has grown alongside the growth and development of the related livestock industry.
Jin Biotech has secured technology to optimize countless variables including the selection and input amount of raw materials for fermentation, the type and quality of starter cultures, temperature, time, and reaction duration. Through patent rights, it has established entry barriers for production technology by product.
In the domestic market, the products already enjoy high recognition and preference. Most products were first developed by Jin Biotech, giving the company a competitive advantage as a pioneer leading the market.
Patent attorney Eom Jeong-han of BLT Patent Law Firm reviewed Jin Biotech’s patent and trademark application status.
Listed companies on the domestic stock market disclose patent acquisition facts through the Financial Supervisory Service’s electronic disclosure system. However, many stock investors tend to overlook patent disclosures.
Not only patents but also trademark registrations serve as important indicators for understanding future corporate value, as they signal the direction a listed company will take. Some patent disclosures even act as direct triggers for stock price increases.
It is not easy for ordinary investors to grasp the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Eom Jeong-han of BLT Patent Law Firm, is reviewing the patent and trademark application status of listed companies through the 'Express Train.'
The Express Train is an abbreviation for a broadcast that diligently searches for stocks surging due to patents.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
